Scholar Rock Holding Corporation $SRRK Holdings Trimmed by Eventide Asset Management LLC

Eventide Asset Management LLC decreased its stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 13.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 2,431,333 shares of the company’s stock after selling 368,123 shares during the period. Scholar Rock accounts for approximately 1.7% of Eventide Asset Management LLC’s portfolio, making the stock its 9th biggest position. Eventide Asset Management LLC’s holdings in Scholar Rock were worth $107,093,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Hudson Bay Capital Management LP increased its holdings in Scholar Rock by 118.5% during the 4th quarter. Hudson Bay Capital Management LP now owns 100,000 shares of the company’s stock worth $4,405,000 after purchasing an additional 640,800 shares during the period. Headlands Technologies LLC purchased a new position in shares of Scholar Rock in the 4th quarter valued at about $584,000. Siren L.L.C. raised its position in shares of Scholar Rock by 17.0% during the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after acquiring an additional 1,575,008 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Scholar Rock by 3.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 702,095 shares of the company’s stock worth $30,927,000 after acquiring an additional 25,060 shares in the last quarter. Finally, State Street Corp raised its position in shares of Scholar Rock by 7.2% during the 4th quarter. State Street Corp now owns 4,034,434 shares of the company’s stock worth $177,717,000 after acquiring an additional 271,331 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Insider Transactions at Scholar Rock

In other Scholar Rock news, COO Keith Woods sold 10,220 shares of Scholar Rock stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $506,605.40. Following the transaction, the chief operating officer directly owned 620,055 shares in the company, valued at approximately $30,736,126.35. This trade represents a 1.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vikas Sinha sold 10,410 shares of Scholar Rock stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $516,023.70. Following the completion of the transaction, the chief financial officer owned 619,856 shares in the company, valued at $30,726,261.92. This trade represents a 1.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 63,491 shares of company stock worth $3,147,249. 13.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Citigroup raised their target price on Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. JPMorgan Chase & Co. raised their target price on Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, March 16th. Truist Financial raised their target price on Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. HC Wainwright raised their target price on Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, BMO Capital Markets raised their target price on Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 4th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Scholar Rock presently has an average rating of “Buy” and a consensus price target of $56.00.

Scholar Rock Trading Down 1.1%

NASDAQ:SRRK opened at $44.18 on Friday. The stock’s 50 day moving average price is $47.88 and its 200 day moving average price is $45.82. The company has a market capitalization of $5.29 billion, a PE ratio of -12.31 and a beta of 0.69. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71. Scholar Rock Holding Corporation has a 52-week low of $27.07 and a 52-week high of $52.19.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period in the previous year, the firm posted ($0.67) earnings per share. On average, research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).